Myelodysplastic syndrome

• STOP-LEUKEMIA: Repurposing metformin as a leukemia-preventive drug in CCUS and LR-MDS Recruiting
  2024-518436-37-01 4 2021-12-01 "Myelodysplastic syndromes (MDS), very low- and low-risk"
• Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Renal Impairment Recruiting
  2024-516291-16-00 3 2021-10-26 "Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS)"
• The study is aimed at evaluating the feasibility of a hypomethylating treatment combined with hematopoietic stem cell transplantation in com … Recruiting
  2023-510515-19-00 5 2020-11-27 "Higher-risk-myelodysplastic syndromes"
• Roll-over study for patients who have completed a prior Novartis sponsored sabatolimab (MBG453) study and are judged by the investigator to … Recruitment ended
  2024-515281-14-00 4 2023-02-13 "intermediate, high or very high risk MDS in adult patients c"
• A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myel … Recruitment ended
  2023-507469-24-00 4 2022-04-30 "Anemia in Patients with Very Low, Low, or Intermediate Risk "
• Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 Recruitment ended
  2024-516293-29-01 4 2022-03-17 "Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS)"
• Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Hepatic Impairment Recruitment ended
  2024-516292-33-00 3 2021-10-22 "Myelodysplastic syndrome (MDS)"
• Double-Blind study comparing venetoclax and azacitidine versus placebo and azacitidine in patients that are newly diagnosed with Higher-Risk … Recruitment ended
  2023-507153-16-00 5 2020-11-18 "Higher-Risk Myelodysplastic Syndrome"
• A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in unfit … Recruitment ended
  2023-503829-18-00 4 2019-12-05 "Acute myeloid leukemia"
• Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio … Recruitment ended
  2022-502832-37-00 5 2019-03-01 "Acute myeloid leukemia"
• To Investigate whether the combination of molidustat and an IDH1 inhibitor (ivosidenib) effectively inhibits leukaemia cells in patients wit … Halted
  2024-514051-15-00 7 2023-07-10 "Adult patients with relapsed or refractory IDH1-mutated AML "
• A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug … Halted
  2024-514588-24-00 7 2021-09-27 "Acute Myeloid Leukaemia (AML)"
• Phase 1 trial of LAVA-1266, a CD123-targeting bispecific Vγ9Vδ2-T cell engager, in patients with CD123 positive relapsed/refractory (R/R) ac … Ended
  2024-518831-12-00 1 2025-04-15 "CD123 positive R/R AML and intermediate risk, high risk, or "
• Prospective and multicentre evaluation of 3 different doses of IV busulfan associated with fludarabine and thymoglobuline in the conditionin … Ended
  2024-516435-27-00 4 2024-11-05 "High-risk myeloïd malignancies"
• Safety, pharmacokinetics, and preliminary efficacy of BYON4413 in acute myeloid leukemia and myelodysplastic neoplasms. Ended
  2023-507781-13-00 1 2024-05-24 "Patients with relapsed/refractory acute myeloid leukemia or "
• A first-in-human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy in subjects with relapsed/refractory Acute Myeloid Leukemia or M … Ended
  2023-507321-42-00 1 2024-02-15 "Myelodysplastic syndrome (MDS)"
• A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myelo … Ended
  2023-505910-10-00 4 2024-01-23 "Relapsed or Refractory High-Risk Myelodysplastic Syndrome"
• A PHASE 1/2 STUDY OF ALX148 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS) (ASPEN-02) Ended
  2024-513993-23-00 9 2022-09-21 "Patients with higher risk myelodysplastic syndrome (MDS) who"
• First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leuk … Ended
  2023-508357-58-00 7 2022-07-04 "Acute lymphocytic leukaemia- Acute myeloid leukaemia refract"
• A study testing increasing amounts (doses) of CC-91633 to find out what dose can be tolerated without serious side effects in patients with … Ended
  2023-503869-34-00 1 2022-03-15 "Acute myeloid leukemia or myelodysplastic syndrome of high r"
• A study to assess the effect of CC-95251 alone and in combination with anti-cancer drugs in subjects with Acute Myeloid Leukemia and Myelody … Ended
  2023-506117-22-00 3 2022-01-05 "Acute Myeloid Leukemia and Myelodysplastic Syndromes"
• A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Interm … Ended
  2024-516296-32-00 3 2021-11-11 "Myelodysplastic Syndromes (MDS)"
• A Phase 1 Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations Ended
  2024-516369-36-00 3 2021-02-09 "- Acute myeloid leukemia - Myelodysplastic syndrome/ Myelopr"
• Study of JNJ-74856665 in patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Ended
  2024-513918-35-00 1 2020-12-22 "Acute myeloid leukemia or Myelodysplastic syndrome"

Showing 25–48 of 50 trials